Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, ...

The approval removes one shareholder hurdle, but the transaction still depends on customary closing conditions and remaining ...

Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

A new Bristol manufacturing facility producing molecules for cell therapies treating conditions including type 1 diabetes and ...

Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the ...

Bio-Techne, a Minneapolis-based provider of life sciences tools, reagents, and diagnostic products, has announced that its shareholders have approved the company's proposed acquisition by Merck KGaA, ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the ...